Nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer

Immunotherapy. 2018 Mar 1;10(6):427-431. doi: 10.2217/imt-2017-0174.

Abstract

Aim: Alongside the proven efficacy, immunotherapy in treatment of malignant diseases can cause immune-related adverse events different from commonly known chemotherapy-related toxicities.

Case presentation: During nivolumab treatment of metastatic squamous cell lung cancer, the patient developed a symptomatic inflammatory myositis confirmed with muscle biopsy and primary hypothyroidism. After initiation of corticosteroids and thyroid hormone replacement, the clinical and laboratory improvement occurred. To the best of our knowledge, this is the first description of a case of nivolumab-induced synchronous manifestation of immune-related myositis and hypothyroidism.

Conclusion: Immunotherapy can trigger a wide spectrum of immune-related adverse events that could occur simultaneously. If not detected and treated, these events could become severe or even fatal and require clinicians' awareness and routine check-ups.

Keywords: immune-related adverse event; immunotherapy; lung cancer; myositis; nivolumab.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Biopsy
  • Drug-Related Side Effects and Adverse Reactions / diagnosis*
  • Drug-Related Side Effects and Adverse Reactions / prevention & control
  • Female
  • Hormone Replacement Therapy
  • Humans
  • Hypothyroidism / diagnosis*
  • Hypothyroidism / etiology
  • Hypothyroidism / prevention & control
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / drug therapy
  • Middle Aged
  • Myositis / diagnosis*
  • Myositis / etiology
  • Myositis / prevention & control
  • Neoplasms, Squamous Cell / diagnosis*
  • Neoplasms, Squamous Cell / drug therapy
  • Nivolumab / adverse effects
  • Nivolumab / therapeutic use*
  • Programmed Cell Death 1 Receptor / immunology
  • Thyroid Hormones / therapeutic use

Substances

  • Adrenal Cortex Hormones
  • Antineoplastic Agents
  • Programmed Cell Death 1 Receptor
  • Thyroid Hormones
  • Nivolumab